Vestmark Advisory Solutions Inc. Buys 40,189 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Vestmark Advisory Solutions Inc. lifted its stake in Twist Bioscience Co. (NASDAQ:TWST) by 64.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 102,928 shares of the company’s stock after purchasing an additional 40,189 shares during the quarter. Vestmark Advisory Solutions Inc. owned about 0.17% of Twist Bioscience worth $4,497,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. Raymond James Financial Inc. bought a new stake in shares of Twist Bioscience in the 4th quarter worth approximately $2,224,000. Arizona State Retirement System raised its holdings in Twist Bioscience by 1.3% in the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company’s stock worth $789,000 after acquiring an additional 219 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in Twist Bioscience in the 4th quarter worth approximately $1,427,000. Victory Capital Management Inc. raised its holdings in Twist Bioscience by 12.2% in the 4th quarter. Victory Capital Management Inc. now owns 372,291 shares of the company’s stock worth $17,300,000 after acquiring an additional 40,482 shares during the last quarter. Finally, Keybank National Association OH raised its holdings in Twist Bioscience by 83.1% in the 4th quarter. Keybank National Association OH now owns 10,334 shares of the company’s stock worth $480,000 after acquiring an additional 4,691 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TWST. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. TD Cowen restated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Wolfe Research began coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Finally, Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $54.40.

Twist Bioscience Price Performance

Shares of TWST opened at $39.18 on Friday. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The firm has a market cap of $2.34 billion, a PE ratio of -11.59 and a beta of 2.15. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The firm has a fifty day simple moving average of $46.91 and a two-hundred day simple moving average of $45.52.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience’s revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.75) EPS. On average, equities analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current year.

Insider Transactions at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,654 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $44.90, for a total value of $74,264.60. Following the completion of the transaction, the chief executive officer now owns 673,064 shares of the company’s stock, valued at approximately $30,220,573.60. This represents a 0.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Adam Laponis sold 5,886 shares of the company’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the transaction, the chief financial officer now directly owns 110,096 shares of the company’s stock, valued at $4,762,752.96. This represents a 5.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,007 shares of company stock worth $1,446,933 in the last three months. Corporate insiders own 3.01% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.